Market Size of Sleep Apnea Implant Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 10.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Sleep Apnea Implant Market Analysis
The sleep apnea implant market is expected to register a CAGR of 10.5% during the forecast period.
COVID-19 had a substantial impact on the sleep apnea implant market since patients with sleep apnea experienced worsening symptoms after affecting COVID-19. The infection promoted airway irritation, making sleep breathing more difficult. Such an important life event is likely to interrupt sleep and have an impact on market growth. For instance, as per the article published in February 2022 in ERJ journal, the researchers showed a significant correlation between increased prevalence and severity of sleep apnea during recovery from illness and the severity of SARS-CoV-2 infection. However, as the restrictions are lifted, and COVID-19 cases are reduced, the market is anticipated to witness growth in the coming years due to the increase in demand for sleep apnea implants, rapid technological advancements, and a rise in sleep disorders.
The growth of the sleep apnea implant market can be attributed to factors such as the rise in sleep disorders and technological advancements in sleep apnea implants. For instance, as per the Advisor 2023 update, about 70 million people in the United States suffer from sleep disorders. In addition, research studies demonstrating the technological advancements of sleep apnea implants are anticipated to boost market growth over the forecast period. For instance, as per the article published in February 2022 in PubMed, mini-implant assisted rapid palatal expansion (MARPE), which increased the size of the nasal and oral cavities and widens the midface, which helped in some patients with OSA therapy by reducing airflow resistance. Furthermore, in February 2022, LivaNova PLC marked its first investigational device exemption study, as the patient was implanted with the company's obstructive sleep apnea (OSA) treatment device. The company's randomized controlled study, 'Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation' (OSPREY), seeks to demonstrate the safety and effectiveness of the LivaNova aura6000 System, an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe OSA.
Thus, due to the rise in sleep apnea cases and the surge in technological advancements in sleep apnea implants, the studied market is anticipated to witness growth over the forecast period. However, the high cost of sleep apnea implants is likely to restrain the market growth over the forecast period.
